Tevogen Bio is a clinical-stage specialty immunotherapy company that focuses on developing off-the-shelf, genetically unmodified T cell therapeutics, particularly utilizing its proprietary ExacTcell™ technology platform. This platform harnesses CD8+ cytotoxic T lymphocytes to create precision T cell therapies aimed at treating infectious diseases, cancers, and neurological disorders. The technology is designed to target antigens present only on diseased cells, thereby preserving healthy cells and enhancing safety. Tevogen's approach addresses significant unmet medical needs, particularly in large patient populations, and aims to make personalized T cell therapies commercially viable and accessible.

In addition to its core immunotherapy technologies, Tevogen Bio is leveraging artificial intelligence (AI) through its Tevogen.AI initiative, in partnership with Microsoft. This collaboration aims to integrate machine learning into preclinical processes to accelerate drug development and reduce costs. By analyzing large genomic datasets and developing proprietary algorithms, Tevogen.AI seeks to enhance target identification and improve understanding of immune responses. This innovative approach not only aims to shorten the typical drug development timeline but also to provide cost savings that can be passed on to patients, aligning with the company's vision of making life-saving therapies accessible to all.

United States

Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company’s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio’s foundational vision is a healthier world through equitable access to lifesaving innovations.

Tevogen Bio

Company Details